Article In Press : Article / Volume 5, Issue 1

Advances in Artificial Consciousness and Traditional Chinese Medicine in Kawasaki Disease Research

Jingwen Zhang1Xiaoxiao Shi1Heping Zi1Taotao Fan1Chunmei Yan1Jun Zhang1Yingxia Yin1Fuyong Jiao1*

1Department of Pediatrics, Children's Hospital,Shaanxi Provincial People's Hospital. Xi‘an, China.

Correspondng Author:

Department of Pediatrics, Children's Hospital, Shaanxi Provincial People's Hospital. Xi'an, China.

Citation:

Fuyong Jiao. et,al. Advances in Artificial Consciousness and Traditional Chinese Medicine in Kawasaki Disease Research. Int. J. Stem Cells Med. Vol. 5 Iss. 1. (2026) DOI: 10.58489/2836-5038/024

Copyright:

© 2026 Fuyong Jiao, this is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • Received Date: 20-12-2025   
  • Accepted Date: 06-01-2026   
  • Published Date: 13-01-2026
Abstract Keywords:

Artificial consciousness, human cognitive, cracked lips, strawberry tongue.

Abstract

Kawasaki disease (KD) is an acute febrile rash illness characterized by systemic vasculitis, primarily affecting children under 5 years of age. [1] Its etiology remains unclear but may involve factors such as infections and immune dysregulation. Traditional Chinese Medicine (TCM) and artificial consciousness (AC), as distinct medical and therapeutic paradigms, have demonstrated potential in the treatment of KD. This paper reviews recent advancements in the application of TCM and AC for KD, explores their integration, and proposes novel strategies for improving KD management. [2,3]

Epidemiology and Clinical Features of Kawasaki Disease

Since its first description in Japan in 1967, KD has been reported worldwide. While epidemiological patterns vary across regions, it predominantly affects children under 5 years old. [4] Classic symptoms include persistent fever, bilateral conjunctival injection, cracked lips, strawberry tongue, edema of the hands and feet, rash, and cervical lymphadenopathy. Cardiac complications, such as myocarditis, pericarditis, and coronary artery aneurysms, pose significant risks. [5] 

Progress in TCM for Kawasaki Disease

TCM offers unique advantages in KD treatment. Although ancient texts lack direct references to KD, modern scholars categorize it under "warm disease" , "epidemic rash" , or "maculopapular rash". TCM employs the "Wei-Qi-Ying-Xue" differentiation system to tailor treatments based on disease stage and patient constitution. [6]  

Etiology and Pathogenesis  
Invasion of Warm-Toxic Pathogens: Latent pathogens reactivate due to external triggers in susceptible children.  
Heat-Stasis Interaction: Heat obstructs meridians, induces blood stasis, and transforms into phlegm-fire.  
Exogenous Warm or Epidemic Toxins: Attack the lung and stomach, leading to heat accumulation in Yangming, skin/mucosal inflammation, and progression to Qi-Nutrient phase blaze.[7,8]  

Syndrome Differentiation and Treatment  
Common TCM patterns and treatments include:  
Wei-Qi Co-Affliction: Clear heat and resolve the exterior with modified Yinqiao Baihu Decoction.  
Dual Blazing of Qi and Nutrient Phases: Cool Qi and nutrient levels using Qingwen Baidu Decoction.  
Residual Heat in Yin Phase: Clear residual heat and nourish Yin with Zhuye Shigao Decoction.  
Qi-Yin Deficiency: Tonify Qi and Yin with Shengmai San.  
5. Toxin-Stasis and Phlegm Obstruction: Clear heat, resolve stasis, and disperse phlegm using combined Qingwen Baidu Decoction and Xiaoluo Pill. [9,10] 
 
Specialized Formulas  
Notable formulas include:  
Jiedu Huayu Dihuang Decoction: Contains Forsythia, buffalo horn, and Rehmannia for heat-clearing and stasis-resolving.  
Qingre Huayu Decoction: Combines buffalo horn, honeysuckle, and Forsythia for cooling blood and detoxification.  
Xuefu Zhuyu Decoction : Modified to promote blood circulation and relieve pain.  

Artificial Consciousness in Medical Applications

Artificial consciousness (AC) simulates human cognitive processes (e.g., perception, decision-making) through AI. [11] Key medical applications include:  

Diagnostic Assistance  
AC analyzes imaging and physiological data to enhance diagnostic accuracy. Deep learning algorithms detect anomalies in medical images, improving efficiency.  

Treatment Planning  
AC generates personalized regimens by evaluating patient data, optimizing drug combinations and therapies.  

Patient Monitoring  
Wearable devices integrated with AC enable real-time monitoring, alerting clinicians to critical changes in patient status. [12] 

Integration of AC and TCM in Kawasaki Disease

Data Mining and Analysis  
AC can analyze TCM literature to identify effective KD treatment patterns, uncovering hidden therapeutic principles.  

Personalized TCM Regimens  
AC synthesizes TCM theory and patient-specific data to recommend optimal herbal formulas and dosages.  

Real-Time Monitoring and Adjustment  
AC tracks treatment responses via wearables, dynamically adjusting TCM protocols to enhance safety and efficacy. [13] 

Intelligent Diagnostic Systems  
Integrated AC-TCM platforms could automate syndrome differentiation, suggest treatments, and provide real-time clinical feedback.[14]  

Prospects and Challenges

Despite promise, challenges persist:  
- Complexity of TCM theory complicates AC interpretation.  
- Technical limitations in AC accuracy and reliability.  
- Resource-intensive development of intelligent systems.  
Future advancements in AC and TCM research, coupled with interdisciplinary collaboration, may overcome these barriers.  

Conclusion

KD remains a serious threat to pediatric health. The integration of TCM and AC offers innovative avenues for treatment through data-driven insights, personalized care, and intelligent monitoring.[15] Cross-disciplinary efforts are essential to advance this emerging frontier in KD management.  

Note: Author names and affiliations are preserved in transliterated form as per academic conventions.

References

  1. Kawasaki, Tomisaku, Fumio Kosaki, Sumio Okawa, Itsuzo Shigematsu, and Hiroshi Yanagawa. "A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan." Pediatrics 54, no. 3 (1974): 271-276.
  2. McCrindle, Brian W., Anne H. Rowley, Jane W. Newburger, Jane C. Burns, Anne F. Bolger, Michael Gewitz, Annette L. Baker et al. "Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association." circulation 135, no. 17 (2017): e927-e999.
  3. Barranco, Caroline. "Kawasaki disease is IL-1β-mediated." Nature Reviews Rheumatology 12, no. 12 (2016): 693-693.
  4. Japan Kawasaki Disease Genome Consortium. "Correction to: Investigation of novel variations of ORAI1 gene and their association with Kawasaki disease (Journal of Human Genetics,( 2019), 64, 6,(511-519), 10.1038/s10038-019-0588-2)." Journal of Human Genetics 64, no. 10 (2019): 1049.
  5. Bijnens, Jeroen, Ludwig Missiaen, Geert Bultynck, and Jan B. Parys. "A critical appraisal of the role of intracellular Ca2+-signaling pathways in Kawasaki disease." Cell Calcium 71 (2018): 95-103.
  6. Hoang, Long Truong, Chisato Shimizu, Ling Ling, Ahmad Nazri Mohamed Naim, Chiea Chuen Khor, Adriana H. Tremoulet, Victoria Wright, Michael Levin, Martin L. Hibberd, and Jane C. Burns. "Global gene expression profiling identifies new therapeutic targets in acute Kawasaki disease." Genome medicine 6, no. 11 (2014): 541.
  7. Fury, Wen, Adriana H. Tremoulet, Virginia E. Watson, Brookie M. Best, Chisato Shimizu, Jennifer Hamilton, John T. Kanegaye et al. "Transcript abundance patterns in Kawasaki disease patients with intravenous immunoglobulin resistance." Human immunology 71, no. 9 (2010): 865-873.
  8. Ben-Sasson, Shlomo Z., Alison Hogg, Jane Hu-Li, Paul Wingfield, Xi Chen, Michelle Crank, Stephane Caucheteux et al. "IL- 1 enhances expansion, effector function, tissue localization, and memory response of antigen-specific CD8 T cells." Journal of Experimental Medicine 210, no. 3 (2013): 491-502.
  9. Noval Rivas, Magali, Youngho Lee, Daiko Wakita, Norika Chiba, Jargalsaikhan Dagvadorj, Kenichi Shimada, Shuang Chen et al. "CD8+ T cells contribute to the development of coronary arteritis in the lactobacillus casei cell wall extract–induced murine model of Kawasaki disease." Arthritis & Rheumatology 69, no. 2 (2017): 410-421.
  10. Lee, Youngho, Danica J. Schulte, Kenichi Shimada, Shuang Chen, Timothy R. Crother, Norika Chiba, Michael C. Fishbein, Thomas JA Lehman, and Moshe Arditi. "Interleukin-1β is crucial for the induction of coronary artery inflammation in a mouse model of Kawasaki disease." Circulation 125, no. 12 (2012): 1542-1550.
  11. de Graeff, Nienke, Noortje Groot, Seza Ozen, Despina Eleftheriou, Tadej Avcin, Brigitte Bader-Meunier, Pavla Dolezalova et al. "European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease–the SHARE initiative." Rheumatology 58, no. 4 (2019): 672-682.
  12. Gorelik, Mark, Sharon A. Chung, Kaveh Ardalan, Bryce A. Binstadt, Kevin Friedman, Kristen Hayward, Lisa F. Imundo et al. "2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of Kawasaki disease." Arthritis care & research 74, no. 4 (2022): 538-548.
  13. Newburger, Jane W., Masato Takahashi, Alexa S. Beiser, Jane C. Burns, John Bastian, Kyung Ja Chung, Steven D. Colan et al. "A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome." New England journal of medicine 324, no. 23 (1991): 1633-1639.
  14. Lei, Wei-Te, Ling-Sai Chang, Bing-Yan Zeng, Yu-Kang Tu, Ritei Uehara, Yutaka J. Matsuoka, Kuan-Pin Su et al. "Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials." EBioMedicine 78 (2022).
  15. Callinan, Laura S., Robert C. Holman, Duc J. Vugia, Lawrence B. Schonberger, and Ermias D. Belay. "Kawasaki disease hospitalization rate among children younger than 5 years in California, 2003–2010." The Pediatric infectious disease journal 33, no. 7 (2014): 781-783.

Become an Editorial Board Member

Become a Reviewer

What our clients say

MEDIRES PUBLISHING

At our organization, we prioritize excellence in supporting the endeavors of researchers and practitioners alike. With a commitment to inclusivity and diversity, our journals eagerly accept various article types, including but not limited to Research Papers, Review Articles, Short Communications, Case Reports, Mini-Reviews, Opinions, and Letters to the Editor.

This approach ensures a rich tapestry of scholarly contributions, fostering an environment ripe for intellectual exchange and advancement."

Contact Info

MEDIRES PUBLISHING LLC,
447 Broadway, 2nd Floor, Suite #1734,
New York, 10013, United States.
Phone: +1 (786) 490-6788
WhatsApp us: WhatsApp - Medires Online
Email: info@mediresonline.org